New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ITAQ/BioSource Therapeutics, Inc. Trademarks Nutraplete Name

BioSource Therapeutics, Inc. Has Obtained Trademark Approval From Patent and Trademark Office For 'Nutraplete'

NEW YORK--(BUSINESS WIRE)--Feb. 7, 2003--Innovative Technology Acquisition Corporation (OTCBB:ITAQ) today announces that its BioSource Therapeutics, Inc. subsidiary is in the final stages for obtaining trademark registration from the US Patent and Trademark Office (PTO) for the name of its product, "Nutraplete". The PTO has completed its formal legal and procedural review of the name and has approved BST's application for publication in the PTO Official Gazette.

BioSource Therapeutics, Inc. is a life science biotechnology corporation dedicated to the research and development of innovative nutraceutical products that address the needs of people with debilitating, chronic diseases. BST is currently developing a product that addresses the needs of people with catabolic caexiea, commonly referred to as "wasting syndrome", an opportunistic infection linked to disease progression and death in diseases such as HIV/AIDS, Hepatitis and Cancer. This product is intended to be eligible for insurance reimbursement, targeting Medicaid populations. BST is positioning itself to be a pioneer in the emerging scientific field of nutritional supplements designed to support traditional medical treatments and therapies.

Innovative Technology Acquisition Corporation identifies and acquires new and innovative nutraceutical products and dietary supplement companies with promising growth potential.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the Company's patent portfolio. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results such as, but not limited to: the ability of the Company to raise necessary capital; to attract and retain effective management; or the failure of third-party contractors to perform their contractual obligations. Prospective investors are also referred to the other risks identified from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.